TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22178174

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM)
Number of subjects: 578

Group type: COMPARATOR
Intervention: Benazepril (Ben)
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: TCM combined with Benazepril (TCM+Ben)
Number of subjects: 578
Study: 20129679

Group type: EXPERIMENTAL
Intervention: 2% viscous lignocaine 4mg/kg body weight topically post-tonsillectomy
Number of subjects: 130

Group type: COMPARATOR
Intervention: Sodium diclofenac 1mg/kg per-rectal post-induction of anaesthesia
Number of subjects: 130
Study: 18049362

Group type: EXPERIMENTAL
Intervention: Toric contact lenses (Biomedics 55, SofLens 66)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Spherical contact lenses
Number of subjects: 15

Group type: COMPARATOR
Intervention: Toric contact lenses vs. Spherical contact lenses
Number of subjects: 15
Study: 15745726

Group type: EXPERIMENTAL
Intervention: Pharmacist-led disease management program
Number of subjects: 217

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 217
Study: 14619641

Group type: EXPERIMENTAL
Intervention: Alendronate, 10 mg, daily for 6 months
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo, daily for 6 months
Number of subjects: 11
Study: 10831522

Group type: EXPERIMENTAL
Intervention: ELCA+PTCA
Number of subjects: 249

Group type: COMPARATOR
Intervention: RA+PTCA
Number of subjects: 249
Study: 8553489

Group type: EXPERIMENTAL
Intervention: Tympanic thermometer (FirstTemp)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Mercury rectal thermometer
Number of subjects: 155
Study: 1760826

Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (ISMN), orally 20 mg 2-3 times daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7051813

Group type: EXPERIMENTAL
Intervention: Topical erythromycin therapy
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Oral erythromycin therapy
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Oral erythromycin therapy (for relapses)
Number of subjects: 41
Study: 31007033

Group type: EXPERIMENTAL
Intervention: Natural Attenuation (NA) combined with 2.5% Surfactant (SF)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Phytoremediation (PH) with Surfactant (SF)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Surfactant (5% SF)
Number of subjects: 4
Study: 30346229

Group type: EXPERIMENTAL
Intervention: Childhood abuse
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Childhood emotional abuse
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Childhood physical abuse
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Childhood sexual abuse
Number of subjects: 548
Study: 26687731

Group type: EXPERIMENTAL
Intervention: Ovariohysterectomy (OHE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-Ovariohysterectomy (non-OHE)
Number of subjects: 60
Study: 24211154

Group type: EXPERIMENTAL
Intervention: Static progressive stretch device plus traditional therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional therapy alone
Number of subjects: 60
Study: 22245666

Group type: EXPERIMENTAL
Intervention: EUS-GBD
Number of subjects: 59

Group type: COMPARATOR
Intervention: PTGBD
Number of subjects: 59
Study: 19493980

Group type: EXPERIMENTAL
Intervention: HIV/AIDS intervention delivered by teachers over a six-month period
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Teacher training and manuals provided
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Large class sizes and teacher resistance
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Student enthusiasm for lessons
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: General disregard for life orientation among students
Number of subjects: 26
Study: 17198120

Group type: EXPERIMENTAL
Intervention: SPRING internship program
Number of subjects: 100

Group type: COMPARATOR
Intervention: Baseline nurses (non-SPRING)
Number of subjects: 100
Study: 15857877

Group type: EXPERIMENTAL
Intervention: Prone sleeping position during active sleep (AS)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Supine sleeping position during active sleep (AS)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Prone sleeping position during quiet sleep (QS)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Supine sleeping position during quiet sleep (QS)
Number of subjects: 63
Study: 12078788

Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin (2 x 10(6) KIU = 280 mg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no aprotinin)
Number of subjects: 29
Study: 9559712

Group type: EXPERIMENTAL
Intervention: Respiratory syncytial virus immune globulin (RSV-IG)
Number of subjects: 39
Study: 7621493

Group type: EXPERIMENTAL
Intervention: Antibacterial varnish (Cervitec) containing 1% chlorhexidine and 1% thymol, applied four times over 3 months.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo varnish control, applied four times over 3 months.
Number of subjects: 18
Study: 2636677

Group type: EXPERIMENTAL
Intervention: Low protein and phosphorus diets
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 96
Study: 31242545

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg·kg‐1)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 28975307

Group type: EXPERIMENTAL
Intervention: Lorazepam + Haloperidol
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo + Haloperidol
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 93
Study: 25740906

Group type: EXPERIMENTAL
Intervention: Green tea extract supplementation (0.56 g/d epigallocatechin gallate + 0.28-0.45 g/d caffeine)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 60
Study: 22830987

Group type: EXPERIMENTAL
Intervention: Jet injection of rapid-acting insulin analogs
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional pen administration of rapid-acting insulin analogs
Number of subjects: 18
Study: 20680244

Group type: EXPERIMENTAL
Intervention: MIS-TKA using quadriceps-sparing approach
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional TKA using medial parapatellar approach
Number of subjects: 50
Study: 19779487

Group type: EXPERIMENTAL
Intervention: Vicorder device
Number of subjects: 122

Group type: COMPARATOR
Intervention: SphygmoCor device
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Vicorder device (adjusted)
Number of subjects: 122
Study: 16708505

Group type: EXPERIMENTAL
Intervention: Special training condition
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard training condition
Number of subjects: 15
Study: 15641602

Group type: EXPERIMENTAL
Intervention: Valdecoxib 40 mg
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Controlled-release diclofenac 75 mg
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Valdecoxib 20 mg
Number of subjects: 269

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study: 11316647

Group type: EXPERIMENTAL
Intervention: Tetracaine aerosol inhalation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Saline aerosol
Number of subjects: 22
Study: 9462247

Group type: EXPERIMENTAL
Intervention: 2-sucrose-phosphate based transport medium (2-SP) with PCR
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: 2-sucrose-phosphate based transport medium (2-SP) with LCR
Number of subjects: 481

Group type: COMPARATOR
Intervention: Shell vial assay
Number of subjects: 481
Study: 8191414

Group type: EXPERIMENTAL
Intervention: Continuous intravenous heparin and oral anticoagulant (AC) treatment
Number of subjects: 90

Group type: COMPARATOR
Intervention: Non-AC treatment with phenylbutazone for ten days
Number of subjects: 90
Study: 3283555

Group type: EXPERIMENTAL
Intervention: Buffered immunoglobulin concentrate against enterotoxigenic E. coli
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control immunoglobulin concentrate (no anti-E. coli activity)
Number of subjects: 20
Study: 31154419

Group type: EXPERIMENTAL
Intervention: Sequential co-enrolment in randomized trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Previous trial participation
Number of subjects: 0
Study: 31066303

Group type: EXPERIMENTAL
Intervention: 0.35 mg oral norethindrone with continuation of transdermal oestradiol patches (NET)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Oestradiol withdrawal by patch removal (E2WD)
Number of subjects: 3
Study: 28801926

Group type: EXPERIMENTAL
Intervention: Internet dissonance-based intervention (DBI-I)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Internet cognitive-behavioral intervention (CBI-I)
Number of subjects: 271

Group type: COMPARATOR
Intervention: No intervention (NI)
Number of subjects: 271
Study: 25322923

Group type: EXPERIMENTAL
Intervention: Souvenaid (medical food) once-daily during the open-label extension study
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Souvenaid (medical food)
Number of subjects: 201
Study: 24115838

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Latanoprost and timolol
Number of subjects: 108
Study: 22180732

Group type: EXPERIMENTAL
Intervention: Absorbable sutures (polyglactin-910)
Number of subjects: 1300

Group type: COMPARATOR
Intervention: Silk sutures (removed at 7-10 days)
Number of subjects: 1300
Study: 19230461

Group type: COMPARATOR
Intervention: Phenylephrine 12 mg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Pseudoephedrine 60 mg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 16877197

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Attention-Control (AC)
Number of subjects: 24
Study: 15209481

Group type: EXPERIMENTAL
Intervention: Mail- and telephone-based weight loss programs
Number of subjects: 1801

Group type: COMPARATOR
Intervention: General sample of overweight members
Number of subjects: 1801
Study: 11523025

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐HuEPO, epoetin alfa)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9442821

Group type: EXPERIMENTAL
Intervention: Caroverine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 8376646

Group type: EXPERIMENTAL
Intervention: Perspective-taking training strategies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 3527811

Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (MPSS), 2 to 3 g i.v. three hours apart within 12 hours of chest pain onset
Number of subjects: 1158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1158

Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (MPSS)
Number of subjects: 1158
Study: 30281694

Group type: EXPERIMENTAL
Intervention: Critical congenital heart disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mortality from congenital heart disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Survival rate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Main cause of death
Number of subjects: 0
Study: 27344822

Group type: EXPERIMENTAL
Intervention: Warm needling therapy and auricular acupuncture (observation group)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Warm needling therapy (control group)
Number of subjects: 110
Study: 25154844

Group type: EXPERIMENTAL
Intervention: LMA group
Number of subjects: 150

Group type: COMPARATOR
Intervention: NLBN group
Number of subjects: 150

Group type: COMPARATOR
Intervention: NLBM group
Number of subjects: 150
Study: 22388234

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 0
Study: 20581338

Group type: EXPERIMENTAL
Intervention: Upper Limb Training and Assessment (ULTrA) program, 40 min/day, 5 days/week for 8 weeks, using a laptop, webcam, target light board, and hand manipulation/discrimination devices.
Number of subjects: 12
Study: 17852547

Group type: EXPERIMENTAL
Intervention: RECESS (n=17): Two additional 30-minute periods of outdoor free play time per day for two days
Number of subjects: 32

Group type: COMPARATOR
Intervention: CON (n=15): Normal classroom schedule
Number of subjects: 32
Study: 15676086

Group type: EXPERIMENTAL
Intervention: Hypothermia treatment (core temperature maintained at 33-35 degrees C for 3-5 days)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Hypothermia treatment
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control (normothermia, no hypothermia treatment)
Number of subjects: 86
Study: 12374248

Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once-weekly
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study: 10808701

Group type: EXPERIMENTAL
Intervention: 17 beta-estradiol 2 mg and norethisterone acetate 1 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 8714860

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard zinc therapy
Number of subjects: 68
Study: 1533724

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (80 micrograms)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 3904873

Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate 100 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Almitrine before BCBR
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Almitrine after BCBR
Number of subjects: 10
Study: 30768919

Group type: EXPERIMENTAL
Intervention: Symptom monitoring with patient-reported outcomes
Number of subjects: 0
Study: 30004957

Group type: EXPERIMENTAL
Intervention: Meibomian gland squeezer
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study: 27749534

Group type: EXPERIMENTAL
Intervention: Cabergoline 0.5 mg, once per week for 3 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 25070995

Group type: EXPERIMENTAL
Intervention: 10,000 PfSPZ
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 25,000 PfSPZ
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 24
Study: 22271539

Group type: EXPERIMENTAL
Intervention: Multicomponent preventive intervention targeting physicians, patients, and families
Number of subjects: 1516

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1516

Group type: EXPERIMENTAL
Intervention: Multicomponent preventive intervention
Number of subjects: 1516
Study: 19644697

Group type: EXPERIMENTAL
Intervention: Drotaverine hydrochloride
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Valethamate bromide
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 19022155

Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy
Number of subjects: 7851

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 7851

Group type: COMPARATOR
Intervention: Heparin + GPI
Number of subjects: 7851
Study: 15849277

Group type: EXPERIMENTAL
Intervention: Open sea scuba air diving to 39 m (30 minutes bottom time)
Number of subjects: 8
Study: 12610862

Group type: EXPERIMENTAL
Intervention: Bleomycin, etoposide, and cisplatin (BEP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin, ifostamide, and either etoposide or vinblastine (VIP or VeIP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDCT) with autologous stem-cell rescue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of new active agents (paclitaxel, gemcitabine, irinotecan)
Number of subjects: 0
Study: 10234295

Group type: EXPERIMENTAL
Intervention: OVEX + TAM
Number of subjects: 1579

Group type: EXPERIMENTAL
Intervention: CHEM
Number of subjects: 1579

Group type: EXPERIMENTAL
Intervention: CHEM + TAM
Number of subjects: 1579

Group type: COMPARATOR
Intervention: TAM
Number of subjects: 1579
Study: 8740091

Group type: EXPERIMENTAL
Intervention: Test formulation (T) of tamoxifen 30 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation (R) of tamoxifen 30 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Test formulation (T) of N-desmethyl-tamoxifen
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation (R) of N-desmethyl-tamoxifen
Number of subjects: 24
Study: 30900512

Group type: EXPERIMENTAL
Intervention: Guided Self‐rehabilitation Contract (GSC) program
Number of subjects: 23
Study: 28105576

Group type: EXPERIMENTAL
Intervention: CBT-I + placebo
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: CBT-I + armodafinil
Number of subjects: 95

Group type: COMPARATOR
Intervention: Armodafinil
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 26474811

Group type: EXPERIMENTAL
Intervention: Thrombectomy followed by PCI
Number of subjects: 10064

Group type: COMPARATOR
Intervention: PCI alone
Number of subjects: 10064
Study: 25149383

Group type: EXPERIMENTAL
Intervention: Ligustrazine intervention (group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nutritional support (group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: FGR group with treatment (animal experiment)
Number of subjects: 60

Group type: COMPARATOR
Intervention: FGR group without treatment (animal experiment)
Number of subjects: 60
Study: 22968413

Group type: EXPERIMENTAL
Intervention: Combination of four probiotics and four fibres
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo group receiving fibres only
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Synbiotics
Number of subjects: 19
Study: 17605839

Group type: EXPERIMENTAL
Intervention: Healthful diet promotion intervention
Number of subjects: 1613

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1613
Study: 16194475

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg/nitrendipine 20 mg (E/N)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Amlodipine 10 mg (A)
Number of subjects: 323
Study: 12970199

Group type: EXPERIMENTAL
Intervention: Off-Pump Coronary Artery Bypass (OPCAB) surgery
Number of subjects: 7386

Group type: COMPARATOR
Intervention: Conventional Coronary Artery Bypass Grafting (CABG) using Cardio-Pulmonary Bypass (CPB) technique
Number of subjects: 7386
Study: 10853971

Group type: EXPERIMENTAL
Intervention: 400 mg once daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: 200 mg twice daily
Number of subjects: 20
Study: 8989057

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1469293

Group type: EXPERIMENTAL
Intervention: Topically applied 8% (w/v) verapamil hydrochloride in propylene glycol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle controls
Number of subjects: 0
Study: 3975747

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg t.i.d.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30955152

Group type: EXPERIMENTAL
Intervention: Initiating joint attention condition
Number of subjects: 37

Group type: COMPARATOR
Intervention: Responding joint attention condition
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both joint attention conditions
Number of subjects: 37
Study: 29316880

Group type: EXPERIMENTAL
Intervention: Highly Structured (HS) format
Number of subjects: 370

Group type: COMPARATOR
Intervention: IMRaD format
Number of subjects: 370
Study: 25840784

Group type: EXPERIMENTAL
Intervention: Preoperative pain peripheralization
Number of subjects: 55
Study: 24205802

Group type: EXPERIMENTAL
Intervention: Adductor canal blockade with 30 ml ropivacaine 7.5 mg/ml (n=36)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Saline (control group, n=35)
Number of subjects: 72
Study: 22494786

Group type: EXPERIMENTAL
Intervention: Vitamin E and C supplementation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Untreated OCU (OC users)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (healthy females not using OCs)
Number of subjects: 120
Study: 21416785

Group type: EXPERIMENTAL
Intervention: Adjustable dosing of budesonide/formoterol (Symbicort, 80/4.5 microg and 160/4.5 microg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fixed dosing of budesonide/formoterol
Number of subjects: 0
Study: 17452579

Group type: EXPERIMENTAL
Intervention: Quetiapine (mean dosage 120 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15860863

Group type: EXPERIMENTAL
Intervention: Receipt of antidepressant medications
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Receipt of counseling services
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Moderate to severe levels of depressive disorder
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Correlates of depression
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Routine screening, evaluation, and treatment
Number of subjects: 472
Study: 12576955

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 69

Group type: COMPARATOR
Intervention: Palpation technique
Number of subjects: 69
Study: 10564319

Group type: EXPERIMENTAL
Intervention: Topical retinaldehyde 0.1% gel combined with topical erythromycin 4% lotion
Number of subjects: 74

Group type: COMPARATOR
Intervention: Topical erythromycin 4% lotion alone
Number of subjects: 74
Study: 8768491

Group type: EXPERIMENTAL
Intervention: Fixed-site remote sensor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mobile remote sensor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple displays monitored
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Event complexity (number of targets and redundancy of target images)
Number of subjects: 0
Study: 1912447

Group type: EXPERIMENTAL
Intervention: 5 micrograms dose of recombinant DNA hepatitis B vaccine (B-Hepavac II)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 10 micrograms dose of recombinant DNA hepatitis B vaccine (B-Hepavac II)
Number of subjects: 67
Study: 7055183

Group type: EXPERIMENTAL
Intervention: terbutaline
Number of subjects: 92

Group type: COMPARATOR
Intervention: ethanol
Number of subjects: 92
Study: 28887255

Group type: EXPERIMENTAL
Intervention: Upper thermal blanket
Number of subjects: 50

Group type: COMPARATOR
Intervention: Underbody thermal blanket
Number of subjects: 50
Study: 27118107

Group type: EXPERIMENTAL
Intervention: Acipimox
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8